From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development |
| |
| Institution: | 1. Department of Immunology, Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Hebei Medical University, 050017, Shijiazhuang, China;2. Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China;3. Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, 10065, USA |
| |
| Abstract: | The global pandemic of COVID-19 caused by SARS-CoV-2 (also known as 2019-nCoV and HCoV-19) has posed serious threats to public health and economic stability worldwide, thus calling for development of vaccines against SARS-CoV-2 and other emerging and reemerging coronaviruses. Since SARS-CoV-2 and SARS-CoV have high similarity of their genomic sequences and share the same cellular receptor (ACE2), it is essential to learn the lessons and experiences from the development of SARS-CoV vaccines for the development of SARS-CoV-2 vaccines. In this review, we summarized the current knowledge on the advantages and disadvantages of the SARS-CoV vaccine candidates and prospected the strategies for the development of safe, effective and broad-spectrum coronavirus vaccines for prevention of infection by currently circulating SARS-CoV-2 and other emerging and reemerging coronaviruses that may cause future epidemics or pandemics. |
| |
| Keywords: | 2019-nCoV SARS-CoV-2 HCoV-19 SARS-CoV Vaccine Cross-protection |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
